Boosting cancer immunotherapy with anti-CD137 antibody therapy

Atsushi Yonezawa, Suparna Dutt, Cariad Chester, Jeewon Kim, Holbrook E. Kohrt

Research output: Contribution to journalReview articlepeer-review


In the past 5 years, immunomodulatory antibodies have revolutionized cancer immunotherapy. CD137, a member of the tumor necrosis factor receptor superfamily, represents a promising target for enhancing antitumor immune responses. CD137 helps regulate the activation of many immune cells, including CD4+ T cells, CD8+ T cells, dendritic cells, and natural killer cells. Recent studies indicate that the antitumor efficacy of therapeutic tumor-targeting antibodies can be augmented by the addition of agonistic antibodies targeting CD137. As ligation of CD137 provides a costimulatory signal in multiple immune cell subsets, combination therapy of CD137 antibody with therapeutic antibodies and/or vaccination has the potential to improve cancer treatment. Recently, clinical trials of combination therapies with agonistic anti-CD137 mAbs have been launched. In this review, we discuss the recent advances and clinical promise of agonistic anti-CD137 monoclonal antibody therapy.

Original languageEnglish
Pages (from-to)3113-3120
Number of pages8
JournalClinical Cancer Research
Issue number14
Publication statusPublished - 2015 Jul 15
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Boosting cancer immunotherapy with anti-CD137 antibody therapy'. Together they form a unique fingerprint.

Cite this